This is a repository copy of Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/136625/

Version: Published Version

Article:
Gajulapalli, Rama Dilip, Dias, Sofia orcid.org/0000-0002-2172-0221, Pattanshetty, Deepak J. et al. (1 more author) (2017) Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. Anatolian Journal of Cardiology. pp. 251-260. ISSN 2149-2263
10.14744/AnatolJCardiol.2017.7672

Reuse
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis

Rama Dilip Gajulapalli, Sofia Dias¹, Deepak J. Pattanshetty², Ganesh Athappan³

Department of Medicine, Cleveland Clinic; Cleveland-Ohio-USA
¹School of Social and Community Medicine, University of Bristol; Bristol-UK
²Case Western University, Metro Health; Cleveland-Ohio-USA
³Department of Interventional Cardiology, Temple University Hospital; Philadelphia-PA-USA

ABSTRACT

Objective: There has been much debate regarding the optimal duration of dual antiplatelet therapy (DAPT) cover after drug eluting stent (DES) implantation. We aimed to assess the relative benefits of shorter and longer durations of DAPT coverage.

Methods: We performed a network meta-analysis (NMA) of all the randomized clinical trials (RCT) comparing different time durations of DAPT cover.

Results: We included 11 unique trials with a total of 33,458 patients; the longest duration of follow-up was 48 months and the shortest was 3 months. NMA results demonstrated that compared with 12 months, longer DAPT of 30 months reduced the hazard ratio (HR) of stent thrombosis (HR, 0.29; 95% CrI, 0.17–0.49). There was no difference in mortality between shorter and longer durations of DAPT except for 30 vs. 48 months (HR, 0.48; 95% CrI, 0.23–0.98). Compared with 12 months, longer DAPT of 30 months reduced the risk of myocardial infarction (HR, 0.47; 95% CrI, 0.37–0.61). Results also demonstrated that compared with 12 months, a shorter-term DAPT reduced the risk of major bleeding (6 months: HR, 0.53; 95% CrI, 0.29–0.98), whereas longer-term DAPT increased the risk of major bleeding (30 months: HR, 1.61; 95% CrI, 1.21–2.15).

Conclusion: As expected, bleeding was less in the shorter duration regimens, whereas the ischemic outcomes were better in the longer duration ones. (Anatol J Cardiol 2017; 18: 251-60)

Keywords: DAPT, PCI, ST, Network meta-analysis

Introduction

The optimal duration of dual antiplatelet therapy (DAPT) after drug eluting stent (DES) implantation has remained in contention, with the recently updated guidelines from major American cardiology societies recommending a minimum of 6 months of aspirin in combination with a P2Y12 inhibitor after DES implantation (1) bringing them in line with the European societies’ recommendations (2) and marking a departure from the past. Shorter DAPT comes with the risk of late and very late stent thrombosis (3, 4), whereas prolonged DAPT comes with an elevated risk of bleeding (5). Defining the fine balance between ischemic benefits and bleeding risks has been elusive thus far. Multiple randomized control trials have shown short-term DAPT to be non-inferior to the current recommended duration of 12 months with similar ischemic outcomes and a lower risk of bleeding (6–9). Conversely, randomized controlled trials on prolonged DAPT beyond 12 months have shown a significant reduction of ischemic events but at the expense of increased bleeding (10).

We therefore conducted a network meta-analysis (NMA) to assess the safety and efficacy of varied durations of DAPT after DES. NMA allows the synthesis of direct and indirect evidence to produce measures of treatment efficacy and ranking of different interventions, while preserving randomization of included trials. This allows an estimation of relative effect estimates for treatments for which no head-to-head comparisons currently exist and can also improve the precision of existing estimates.

Methods

Study design and definitions

In this NMA, we compared four outcomes: all-cause mortality, myocardial infarction (MI), stent thrombosis (ST), and major bleeding (MB), for variable durations of DAPT (short and prolonged). Trials comparing variable durations of DAPT were iden-
tified and analyzed. We restricted our analyses to randomized controlled trials. The present NMA review was done according to PRISMA guidelines for performing NMA (11).

Search strategy
The authors collected data from four online databases: Medline (PubMed), Cochrane Collaboration of Clinical Trials, Clinicaltrials.gov, and Google Scholar. The searches were limited by date and extended from 2000 to October 25, 2015. The search objective was to identify all randomized controlled trials comparing varying durations of DAPT.

The search terms used were “DAPT,” “dual antiplatelet,” “clopidogrel,” “Plavix,” “thienopyridines,” and “P2Y12 inhibitors.” We limited the search to English language reports and randomized controlled trials. We screened citations at the title and abstract level and retrieved full reports if they were randomized trials comparing variable durations of DAPT after DES implantation and provided information on all-cause mortality, MI, ST, and bleeding. The full texts of all potential articles were reviewed in detail. The bibliography of retained studies was used to seek additional relevant studies.

Inclusion and exclusion criteria
Studies were included if the following criteria applied: (a) comparative trials of variable DAPT duration, (b) enrolled patients with DES implantation, and (c) reported on at least one of the following outcomes: all-cause mortality, MI, MB, or ST. When two similar studies were reported from the same institution or author, the most recent publication or the most relevant one was included in the analysis.

Studies were excluded if any of the following criteria applied: (a) nonrandomized studies, (b) enrolled patients with no DES implantation, (c) outcomes of interest were not clearly reported or were impossible to extract or calculate from the published results, (d) single-arm studies, or (e) duplicate publications.

Study end-point
The end points analyzed were all-cause mortality, bleeding, MI, and ST. All end points were evaluated according to per protocol and individual study definitions (Table 1).

Statistical analysis
A Bayesian NMA, using noninformative priors, was conducted on the hazard ratio (HR) scale to account for the varying follow-up times across studies. Relative effect estimates are presented as median HRs and 95% credible intervals (CrI). Both fixed and random effects models were fitted and compared based on residual deviance and deviance information criteria (DIC) (12, 13). The model with the smallest DIC was preferred as being the best compromise between fit and complexity. A small difference in DIC between the fixed and random effects models (3–5 points) implies that the better fit obtained by adding random effects does not justify the additional complexity, in which case we would report the results from a fixed effects model’s results. Between-studies heterogeneity estimates from random effects models are presented as median and 95% CrI.

A DAPT duration of 12 months was selected as the reference treatment to aid interpretation, although results are not sensitive to this choice (14).

Inconsistency, that is the agreement between direct and indirect evidence on the same comparisons, was tested in the single available closed loop of treatment comparisons by comparing the direct and indirect estimates obtained from an unrelated mean effects model (14). This technique allows estimation of relative effects based only on direct RCT data, which can then be compared to the indirect evidence generated according to the Bucher method (15). The difference between these contributions can be quantified using a Bayesian p-value indicating the probability that there are differences in relative effects calculated using direct and indirect evidence.
Probabilities of each outcome on the reference treatment were calculated by pooling the evidence from all RCTs that compared it using a separate random effects meta-analysis model (16). These probabilities were then used to calculate the expected number of people who need to receive DAPT at each duration to incur (or avoid) an event at a given time point [number needed to treat (NNT) and number needed to harm (NNH)] (13). Ranking probabilities for each treatment and outcome were also calculated. The statistical analyses were conducted in WinBUGS 1.4.3 (The BUGS Project, MRC Biostatistics Unit, University of Cambridge, UK) (17) using the code adapted from the Dias et al. (18–20). Noninformative priors were used for all relative treatment effects and heterogeneity parameters. Three independent chains were run and checks for convergence and autocorrelation were carried out using the Brooks–Gelman–Rubin tools and by inspecting trace and autocorrelation plots. All results were based on postconvergence 150,000 iterations (50,000 on each of the three independent chains).

Results

Using the keyword search, 18,467 reports were identified of which 1122 relevant publications were selected by screening at the abstract and title level (Fig. 1). By applying the inclusion and exclusion criteria, 10 unique trials were selected for the meta-analysis. The OPTIDUAL trial was also included as a late addition based on it meeting the appropriate criteria. These 11 unique trials included a total of 33,458 patients. The longest duration of follow-up was 48 months while the shortest was 3 months. The majority of the dual antiplatelet agents were aspirin or acetylsalicylic acid and clopidogrel, while prasugrel was sparingly used. All the included trials reported end points including ST, MI, mortality, and bleeding. The main study details and clinical characteristics of enrolled patients are shown in Table 2a, b.

There were two studies that compared 3 months vs. 12 months, three that compared 6 months vs. 12 months, two that compared 6 months vs. 24 months, three that compared 12 vs. 30 months (DES LATE, which compared 12 months vs. 36 months was included for ease of comparison), and one that compared 12 vs. 48 months of DAPT after DES implantation. The treatment network is presented in Figure 2.

Fixed effect models were found to fit the data well for all outcomes, thus all results presented are from fixed effect models. There was no evidence of inconsistency between direct and indirect evidence for any outcome with Bayesian p-values ranging from 0.09 (ST) to 0.82 (bleeding). The probability rankings of the treatment durations for each outcome are shown in Figure 3. We also assessed the quality of outcome and interpretations using the GRADE recommendation (Table 3a, b). The probabilities and numbers needed to treat based on our NMA are provided in Tables 4 and 5.

Stent thrombosis (Fig. 4a)

NMA results demonstrated that compared with 12 months, longer DAPT of 30 months reduced HR of ST (HR, 0.29; 95%
CrI, 0.17–0.49). Similarly, 30 months of DAPT was better than 3 months of DAPT to prevent ST (HR, 0.29; 95% CrI, 0.12–0.70). The probability that 30 months of DAPT is the best of the durations compared at reducing ST is 96%. There was no difference in ST between 3 months vs. 12, 6, 24, or 48 months; 6 months vs. 12, 24, 30, or 48 months; 24 months vs. 48 months; and 30 months vs. 48 months. The number needed to prevent one ST with 30 months of DAPT compared with 12 months was 327 (95% CrI, 116–939) vs. 816 (95% CrI, 287–2346).

**Mortality (Fig. 4b)**

NMA results demonstrated that there was no difference in mortality between short and longer durations of DAPT except for 30 months vs. 48 months (HR, 0.47; 95% CrI, 0.37–0.61). Similarly 30 months of DAPT was better than 3 (HR, 0.42; 95% CrI, 0.26–0.68), 6 (HR, 0.47; 95% CrI, 0.37–0.61). 30 months duration reduces mortality compared with 12 months was 84 (95% CrI, 61–165) vs. 325 (95% CrI, 240–640). There was no significant effect noted when 30 months was compared with 12 months.

**MI (Fig. 4c)**

NMA results demonstrated that compared with 12 months, longer DAPT of 30 months reduced the hazard risk (HR) of MI (HR, 0.47; 95% CrI, 0.37–0.61). Similarly 30 months of DAPT was better than 3 (HR, 0.42; 95% CrI, 0.26–0.68), 6 (HR, 0.47; 95% CrI, 0.37–0.61). 30 months duration reduces mortality compared with 12 months was 84 (95% CrI, 61–165) vs. 325 (95% CrI, 240–640). There was no significant effect noted when 30 months was compared with 12 months.

---

**Table 2a. Study characteristics of the randomized trials**

| Study names  | Year | Comparison (Time of DAPT use in months) | N   | Age, years | Sex | DM | Clopidogrel | Prasugrel |
|-------------|------|----------------------------------------|-----|------------|-----|----|-------------|----------|
|             |      |                                        | S L | S L        | S L | S L| S L         | S L      |
| DAPT        | 2014 | 12 vs. 30                              | 4941| 5020       | 62  | 62 | 26          | 30       |
| ITALIC      | 2014 | 6 vs. 24                               | 912 | 910        | 62  | 62 | 19          | 36       |
| RESET       | 2012 | 3 vs. 12                               | 1059| 1058       | 62  | 62 | 36          | 30       |
| ARCTIC      | 2014 | 12 vs. 30                              | 624 | 635        | 64  | 64 | 19          | 36       |
| SECURITY    | 2014 | 6 vs. 12                               | 682 | 717        | 65  | 66 | 22          | 30       |
| EXCELLENT   | 2012 | 6 vs. 12                               | 722 | 721        | 63  | 62 | 35          | 39       |
| DES LATE    | 2014 | 12 vs. 36                              | 2514| 2531       | 62  | 63 | 30          | 28       |
| OPTIMIZE    | 2013 | 3 vs. 12                               | 1563| 1556       | 61  | 62 | 37          | 35       |
| PRODIGY     | 2012 | 6 vs. 24                               | 983 | 987        | 68  | 68 | 24          | 25       |
| ISAR-SAFE   | 2015 | 6 vs. 12                               | 1997| 2003       | 67  | 67 | 19          | 25       |
| OPTIDUAL    | 2015 | 12 vs. 48                              | 690 | 695        | 64  | 64 | 21          | 32       |

Age given in Mean or Median as provided; DAPT - dual antiplatelet treatment; DM - diabetes mellitus %; L - longer duration group; N - number of subjects; NA - not available; S - short duration group; Sex - female %; vs - versus; year, study published

**Table 2b. Study characteristics of the randomized trials**

| Study names  | Stents per patient | ACS | DES generation | Type of study | Independent adjudication |
|--------------|--------------------|-----|----------------|---------------|--------------------------|
|              |                    |     | First          | Second        |                          |
| DAPT         | 1.45               | 43  | 38            | 60            | Double blinded RCT       | Yes                      |
| ITALIC       | 1.6                | 24  | 0             | 100           | Open Label RCT           | Yes                      |
| RESET        | 1.3                | 54  | 21            | 85            | Open Label RCT           | Yes                      |
| ARCTIC       | –                  | –   | 40            | 60            | Open Label RCT           | Yes                      |
| SECURITY     | 1.6                | 38  | 0             | 100           | Open Label RCT           | Yes                      |
| EXCELLENT    | 1.6                | 52  | 25            | 75            | Open Label RCT           | Yes                      |
| DES LATE     | 1.3*               | 61  | 64            | 30            | Open Label RCT           | Yes                      |
| OPTIMIZE     | 1.6                | 32  | 0             | 100           | Open Label RCT           | Yes                      |
| PRODIGY      | 1.86               | 75  | 25            | 50            | Open Label RCT           | Yes                      |
| ISAR-SAFE    | 1.68               | 40  | 10            | 89            | Double blinded RCT       | Yes                      |
| OPTIDUAL     | 1.5                | 34  | 35            | 60            | Open Label RCT           | Yes                      |

ACS - acute coronary syndrome; DES - drug eluting stent; RCT - randomized controlled trial; ACS&DES figures given in %
0.30–0.72), or 24 months (HR, 0.54; 95% CrI, 0.34–0.86) of DAPT to prevent MI. There was no difference in MI between 30 and 48 months of DAPT (HR, 1.42; 95% CrI, 0.63–3.21). There was no difference in MI between the other durations of DAPT. The probability that 30 months of DAPT is the best of the durations compared at preventing MI is 80%. The number needed to prevent one MI with 30 months of DAPT compared with 12 months was 91 (95% CrI, 51–165) vs. 225 (95% CrI, 126–411).

**Bleeding (Fig. 4d)**

NMA results demonstrated that compared with 12 months, shorter DAPT reduced the risk of MB (6 months: HR, 0.53; 95% CrI, 0.53–0.98), whereas longer DAPT increased HR of MB (30 months: HR, 1.61; 95% CrI, 1.21–2.15). Similarly, 3 months of DAPT was better than 24 months (HR, 2.50; 95% CrI, 1.08–5.85) and 30 months (HR, 2.66; 95% CrI, 1.25–5.72). Six months DAPT was also better than 24 months (HR, 2.85; 95% CrI, 1.48–5.44) and 30 months (HR, 3.02; 95% CrI, 1.54–6.00) of DAPT to prevent MB. The duration with the highest probability of being the best of the durations compared at preventing bleeding is 6 months, with 57% probability. The number needed to cause harm or one MB event with 30 months of DAPT compared with 12 months was 139 (95% CrI, 434–64) vs. 343 (95% CrI, 1076–157).

### Table 3a. GRADE assessment

| Outcome                  | Type of evidence | Quality | Consistency | Directness | Effect size | Overall grade |
|--------------------------|------------------|---------|-------------|------------|-------------|---------------|
| Stent thrombosis         | 4+               | 0       | 0           | 0          | 0           | 3             |
| Myocardial infarction    | 4+               | 0       | 0           | 0          | 0           | 3             |
| Mortality                | 4+               | 0       | 0           | 0          | 0           | 3             |
| Bleeding                 | 4+               | 0       | 0           | 0          | 0           | 3             |

### Table 3b. GRADE assessment scoring system (Adapted from BMJ Clinical Evidence 2012*)

| Type of evidence | Scored on | Quality |
|------------------|-----------|---------|
|                  | +4        | RCT     |
|                  | +2        | Observational evidence |

| Quality |
|---------|
| Based on Blinding and allocation, follow-ups, withdrawals, sparse data, and methodological concerns |
| Score 0 | No problems |
| –1 Problem with 1 element |
| –2 Problem with 2 elements |
| –3 Problem with 3 or more elements |

| Consistency |
|-------------|
| Based on Degree of consistency of effect between or within studies |
| Score +1 Evidence of dose response across or within studies |
| 0 All/most studies show similar results |
| –1 Lack of agreement between studies |

| Directness |
|------------|
| Based on The generalizability of population and outcomes from each study to population of interest |
| Score 0 Population and outcomes broadly generalizable |
| –1 Problem with 1 element |
| –2 Problem with 2 or more elements |

| Effect size |
|------------|
| Based on The reported OR/RR/HR for comparison |
| Score 0 Not all effect sizes >2 or <0.5 and significant; or if OR/RR/HR not significant |
| +1 Effect size >2 or <0.5 for all studies/meta-analyses included in comparison and significant |
| +2 Effect size >5 or <0.2 for all studies/meta-analyses included in comparison and significant |

**Final GRADE score:** High (4 points overall), Moderate (3 points), Low (2 points), and Very low (one or less).

(*http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665072.html). HR - hazards ratio; OR - odds ratio; RCT - randomized controlled trial, RR - relative risk
Table 4. Probability of an event and 95% CrI at given time points

| Months | Stent thrombosis | Bleeding | MI | Mortality |
|--------|------------------|----------|----|-----------|
|        | Median           | 95% CrI  | Median | 95% CrI | Median | 95% CrI | Median | 95% CrI |
| 3      | 0.000            | (0.000, 0.001) | 0.002 | (0.001, 0.003) | 0.002 | (0.001, 0.004) | 0.002 | (0.001, 0.003) |
| 6      | 0.001            | (0.000, 0.002) | 0.004 | (0.002, 0.006) | 0.004 | (0.002, 0.007) | 0.004 | (0.003, 0.006) |
| 12     | 0.002            | (0.001, 0.004) | 0.008 | (0.005, 0.012) | 0.009 | (0.005, 0.015) | 0.008 | (0.005, 0.013) |
| 24     | 0.004            | (0.001, 0.009) | 0.015 | (0.010, 0.023) | 0.017 | (0.010, 0.029) | 0.017 | (0.011, 0.026) |
| 48     | 0.007            | (0.002, 0.017) | 0.030 | (0.019, 0.046) | 0.034 | (0.019, 0.057) | 0.033 | (0.022, 0.050) |

Reference treatment (12 months duration); CrI, credible interval; MI, myocardial infarction. Probabilities of each outcome on the reference treatment were calculated by pooling the evidence from all RCTs that compared it using a separate random effects meta-analysis model.

Table 5. NNT for an additional event

| Months | Stent thrombosis | Bleeding | MI | Mortality |
|--------|------------------|----------|----|-----------|
|        | Median           | 95% CrI  | Median | 95% CrI | Median | 95% CrI | Median | 95% CrI |
| 3      | 3259             | (1145, 9377) | 1362 | (4289,621) | 894 | (497,1637) | 1288 | (9577,2542) |
| 6      | 1630             | (573, 4690) | 683  | (2147,312) | 448 | (250,820) | 646  | (4800,1274) |
| 12     | 816              | (287, 2346) | 343  | (1076,157) | 225 | (126,411) | 325  | (2409,640) |
| 24     | 409              | (144, 1173) | 173  | (541,79) | 113 | (64,207) | 164  | (1216,323) |
| 30     | 327              | (116, 939) | 139  | (434,64) | 91  | (51,165) | ***  | *** |
| 48     | 205              | (73, 588) | 88   | (273,41) | 58  | (33,104) | 84   | (619,165) |

NNT for an additional event compared with 12 months; CrI - credible interval; MI - myocardial infarction. Probabilities used to calculate the expected number of people who need to receive DAPT at each duration.

Figure 3. Rankogram probability plots
Discussion

DAPT after PCI has been a cornerstone as it has been shown to be beneficial in reducing complications including ST. It is a class I A recommendation from major societies including the American College of Cardiology (1). However, the optimal duration of DAPT after PCI has been a source of discussion with varying consensus.

The study herein is the largest meta-analysis to be reported in the literature and the only one to compare as many different durations of DAPT (3, 6, 12, 24, 30, and 48 months). We have performed an NMA comparing different durations of DAPT from studies incorporating nearly 30,000 patients undergoing PCI with DES implantation. Our findings are consistent with the current thoughts on DAPT: longer duration of DAPT is associated with increased risk of bleeding and reduced risk of ST and MI. We also found no difference in mortality between shorter or longer duration of DAPT. However, we were able to delve further into the data and show that one significantly reduced risks of ST and MI are only seen with durations of DAPT >24 months and that

| Duration in months | HR of Y compared X | Median | 95% Crl      |
|--------------------|--------------------|--------|--------------|
|                    |                    |        |              |
| X                  | Y                  |        |              |
| 12                 | 3                  | 1.12   | (0.75, 1.86) |
| 12                 | 6                  | 1.07   | (0.71, 1.45) |
| 12                 | 24                 | 0.87   | (0.59, 1.28) |
| 12                 | 30                 | 0.47   | (0.37, 0.61) |
| 12                 | 48                 | 0.67   | (0.31, 1.45) |
| 6                  | 6                  | 0.91   | (0.53, 1.55) |
| 6                  | 24                 | 0.78   | (0.45, 1.36) |
| 6                  | 30                 | 0.42   | (0.26, 0.68) |
| 6                  | 48                 | 0.60   | (0.25, 1.44) |
| 24                 | 6                  | 0.86   | (0.60, 1.23) |
| 24                 | 30                 | 0.47   | (0.30, 0.72) |
| 24                 | 48                 | 0.66   | (0.28, 1.55) |
| 30                 | 3                  | 0.54   | (0.34, 0.86) |
| 30                 | 48                 | 0.77   | (0.33, 1.83) |

HR>1 favors X; HR<1 favors Y

Figure 4. Hazard ratios (HR) of stent thrombosis (a), mortality (b), myocardial infarction (c) and bleeding (d).
while preventing one myocardial infarction and one ST with 30 months of DAPT, approximately 3 and 11 patients, respectively, developed one MB complication.

As shown by the majority of previous studies, incidence of ST tended to decrease as the DAPT duration increased (21–23). However, our analysis showed that ST rates were significantly lower only when DAPT was continued for 30 months when compared with any duration up to and including 24 months. It would seem that the advantage is highest when compared with durations of 3, 6, or 12 months. Comparisons of differing DAPT durations up to 24 months did not have any statistical benefit. It may seem that continuing DAPT beyond 24 months may reduce continued rates of very late ST. In the included trials, PCI patients with both 1st and 2nd generation DES were enrolled. Since late and very late ST has been shown to be more significant in 1st generation DES compared with 2nd generation DES, it can be speculated that the continuation of DAPT beyond 2 years reduced the elevated rates of very late ST in 1st generation DES, contributing to the overall statistical benefit. The combined analysis of all SPIRIT studies (24) showed the risk of definite and probable ST after the 1st year and up to the 3rd year to be 0.4% with EES and 0.70% with PES, respectively. The lower risk of late ST with second-generation DES compared with first-generation DES challenges the need for prolonged DAPT to prevent stent thrombosis. In our analysis, the number needed to prevent one ST by prolonging DAPT for 30 months as opposed to the standard therapy was 327. Therefore, whether prolonged DAPT duration has clinical significance in preventing ST post 2nd generation DES remains debatable.

Similar to ST, MI rates seem to improve with longer duration of DAPT (10). DAPT coverage of 30 months had the lowest rates of MI. In our analysis, the number needed to prevent one MI by prolonging DAPT for 30 months as opposed to the standard therapy was 91. In the PEGASUS trial (25), patients who were 1–3 years post-MI and had specific high-risk characteristics (aged ≥65 years and had diabetes mellitus, second prior spontaneous MI, multi-vessel CAD, and chronic renal dysfunction) were enrolled to receive either DAPT or aspirin alone for a median follow-up of 33 months. Both 90 mg and 60 mg of ticagrelor significantly reduced MI (HR, 0.83; 95% CrI, 0.72–0.95) over the study period compared with aspirin alone. However, reduction in MI was accompanied by increased MB (1.85% vs. 1.09%; RR, 1.73; 95% CrI, 1.19–2.50; p = 0.004; NNH, 132). In our analysis, the prevention of one MI with prolonged DAPT was estimated to occur at the expense of three major bleeds.

As expected, longer duration of DAPT increased the risk of MB. Bleeding during 3 months or 6 months of DAPT was less than that at 12, 24, or 30 months. The only discrepancy was the lack of significant difference between 3 months vs. 12 months of DAPT (HR, 0.61; 95% CrI, 0.30–1.22). Standard 12 months duration of DAPT was similarly better than prolonged DAPT. Recent analysis by Palmerini et al. (26) concluded that at 1 year, bleeding was lower with shorter duration (<6 months) compared with 1 year of therapy and there was no significant difference in MACE. We have been able to show that the trends for bleeding worsen as the duration of DAPT coverage lengthens up to 30 months compared with just 1 year. While we did not look specifically at MACE, we were able to show that the mortality risk did not differ at various time intervals, irrespective of the duration of therapy. This reinforces the findings by Palmerini et al. (26) albeit over a longer term. Another recent analysis by Giustino et al. (22) showed that longer duration DAPT correlated to lower risk of ST and MI and increased the bleeding risk.

In the DAPT trial (10), prolonged DAPT was however associated with an increased risk of noncardiac death. Similarly, in the meta-analysis by Palmerini et al. (26), prolonged DAPT was associated with increased mortality. Our meta-analysis incorporates the OPTIDUAL study published by Helft et al. (27), which randomized 1385 patients to DAPT with clopidogrel for 12 months vs. 48 months. They found a trend toward decreased mortality without statistical significance in the long term DAPT group but also saw no increase in bleeding risk with longer therapy. However, we found no mortality benefit with longer duration DAPT compared with shorter duration. Though ST and MI rates were reduced with longer duration DAPT, this did not lend a mortality benefit. This could be due to higher bleeding risk negating any mortality benefit of reduced ST and MI rates. One aspect to note was that compared to 30 months, 48 months therapy seemed to reduce mortality but the risk of ST, bleeding, or MI was no different. It is unclear if this pertains to only cardiac deaths or combined mortality. Prior analysis seems to suggest that while longer DAPT lowers many complications, some risks seem to plateau over time including very late ST (28). Whether the 48 month duration in particular was helpful in preventing cerebrovascular events is unclear.

**Study limitations**

Without access to patient level data, we were unable to further assess the effect of differing antiplatelet agents (clopidogrel vs. ticagrelor vs. prasugrel). We were also unable to assess the effect of stent generation on patient outcomes and the risk of ST and MI. In fact, the lack of this data and lack of standardization across studies may obscure the complete clinical picture and actual risk and benefits of DAPT duration.

Although we carried out NMA on the HR scale, which accounts for the different duration of follow-up in each study, this assumes proportional hazards throughout the period of study. Individual patient data would allow exploration of other assumptions.

**Conclusion**

In this NMA of randomized trials comparing different durations of DAPT after DES implantation, we found that there is probably no benefit in extending DAPT beyond 12 months. The
lower frequency of MI and ST likely comes at the price of increased MB. Based on our calculation of NNT vs. NNH, 30 months of DAPT may have an unnecessarily high risk of bleeding in comparison to the more modest reduction in the risk of MI or ST. DAPT after DES implantation should be limited to 6 months as suggested by various updated guidelines recently. Prolonging DAPT beyond this time period may have benefits in some patients but is independent of stent implantation.

Disclosures: Dr Sofia Dias is co-applicant on a Medical Research Council (UK) Grant, which is also part-funded by Pfizer that partly funds a member of staff. No funding and no disclosures for all other authors.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept – R.D.G., G.A.; Design – S.D., G.A.; Supervision – G.A.; Data collection &/or processing – R.D.G., D.J.P.; Analysis &/or interpretation – S.D., G.A.; Literature search – R.D.G., G.A.; Writing – R.D.G., G.A.; Critical review – R.D.G., G.A.

References

1. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68: 1082-1115.

2. Windecker S, Kohl P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.

3. Mehran R, Baber U, Step PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-22.

4. Van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399-409.

5. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomised trials. Eur Heart J 2012; 33: 641-56.

6. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shemp P, Cutlip DE, Step PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-66.

7. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med 2015; 162: 777-84.

8. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J Royal Statistical Society: Series B (Statistical Methodology) 2002; 64: 583-639.

9. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pair-wise and network meta-analysis of randomized controlled trials. Med Decis Making 2013; 33: 607-17.

10. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013; 33: 641-56.

11. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.

12. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 5: the baseline natural history model. Med Decis Making 2013; 33: 657-70.

13. Lunn D, Jackson C, Best N. The BUGS book: A Practical Introduction to Bayesian Analysis. Boca Raton, FL, CRC Press 2013. p. 381.

14. Dias S, Welton NJ, Sutton AJ. NICE DSU Technical Support Document 2: A generalised linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials. 2011.

15. Dias S, Welton NJ, Sutton AJ. NICE DSU Technical Support Document 5: Evidence synthesis in the baseline natural history model. 2011.

16. Dias S, Welton NJ, Sutton AJ. NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials. 2011.

17. Uedal JA, Bonaca MP, Collet JP, Lincoll AM, Kereiakes DJ, Costa F, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2015; 37: 390-9.

18. Giustino G, Baber U, Sarto S, Mehran R, Mastoros I, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015; 65: 1298-310.

19. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015; 350: 1618.

20. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of...
the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013; 6: 914-22.

25. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Eng J Med 2015; 372: 1791-800.

26. Palmerini T, Sangiorgi D, Valgimigli M, Biondi-Zoccai G, Feres F, Abizaid A, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 2015; 65: 1092-102.

27. Helft G, Le Feuvre C, Georges JL, Carrie D, Leclercq F, Eltchaninoff H, et al. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTIMAL DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials 2013; 14: 56.

28. Leon MB, Allocco DJ, Dawkins KD, Baim DS. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. JACC Cardiovascular Interv 2009; 2: 504-12.